mercredi 30 septembre 2026
RechercherExplore
fr.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 20, 2026

Which Pharma Stock Stands Taller Right Now: LLY or PFE?

View original at finance.yahoo.com
Which Pharma Stock Stands Taller Right Now: LLY or PFE? Eli Lilly & Company LLY and Pfizer PFE are large-cap U.S. pharmaceutical leaders, each backed by diversified product portfolios and robust R&D engines…
Opening lines of the source · short snapshot — read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Lilly's 2026 sales expected to increase 22.6% year-over-year

    80% confidence

  • Cost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027

    80% confidence

  • Data readouts from three phase III studies on retatrutide for treating obesity expected in the second half of 2026

    80% confidence

  • Pfizer's 2026 sales expected to decline 2.1% year-over-year

    80% confidence

  • Lilly is a clear winner over Pfizer due to exceptional growth from Mounjaro and Zepbound, product and pipeline portfolio in high-growth therapeutic areas like obesity, robust growth prospects and bullish analyst sentiment

    80% confidence

  • Loss of exclusivity cliff expected to hurt sales by approximately $1.5 billion in 2026

    80% confidence

  • New and acquired products expected to deliver double-digit growth in 2026

    80% confidence

  • COVID revenues expected to be around $5 billion in 2026, $1.5 billion less than expected sales of about $6.5 billion in 2025

    80% confidence

  • Pfizer's 2026 EPS expected to decline 4.2% year-over-year

    80% confidence

  • Mounjaro and Zepbound are expected to continue to see strong demand in 2026

    80% confidence

  • Lilly's 2026 EPS expected to increase 39.5% year-over-year

    80% confidence

  • Orforglipron has potential to be approved and launched in 2026

    80% confidence

  • Metsera candidates expected to generate billions of dollars in peak sales

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
The Agentic Takeover of the CFO's Office
Enterprise finance software vendors—BlackLine, OneStream, Numero AI, and Oracle—are racing to embed autonomous AI agents into core financial operations (close, consolidation, reporting), backed by consolidation M&A (Numero-Royu, BlackLine-WiseLayer), fresh leadership hires, and survey data showing nearly a quarter of CFOs plan to boost AI spending over 50%. Adoption momentum is strong even as at least one bellwether (Oracle) sees its stock lag year-to-date, suggesting the market hasn't yet fully priced in the shift from AI-as-feature to AI-as-agent in finance.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Morgan Stanley & Co. LLC
Two significantly different EPS values (10.21 vs 2.68 USD_per_share) are reported for Morgan Stanley on the same observation date (2025-12-31). Fact A specifies FY 2025, while Fact B's 'N/A' fiscal period is ambiguous. If both represent FY 2025 annual EPS, these values directly conflict. The magnitude of the difference (3.8x) is too large to attribute to rounding or minor calculation variations. The missing fiscal period in Fact B raises data quality concerns, but same-date observation + same attribute should reference the same period.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,984
faits reliés à leur source — et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,984 faits vérifiés avec la source5,315 documents sources archivés
Interrogez ces données → isubstrate.com
Which Pharma Stock Stands Taller Right Now: LLY or PFE? — Source | Via News | fr.VIA.NEWS